Lipoic acid modulates inflammatory responses of monocytes and monocyte-derived macrophages from healthy and relapsing-remitting multiple sclerosis patients

Area of Science:

• Neuroimmunology
• Cellular and Molecular Medicine

Background:

• Multiple sclerosis (MS) is a neuroinflammatory disease where oxidative stress and inflammation play key roles.
• Macrophages in MS lesions produce molecules that drive demyelination and myelin degradation.
• Lipoic acid (LA) possesses antioxidant and anti-inflammatory properties, showing protective effects in inflammatory conditions.

Purpose of the Study:

• To investigate the mechanisms by which lipoic acid (LA) may reduce inflammatory activity in multiple sclerosis (MS).
• To evaluate the impact of LA on inflammatory cytokines, phagocytosis, and cyclic adenosine monophosphate (cAMP) in monocytes and monocyte-derived macrophages (MDMs).

Main Methods:

• Utilized monocytes and MDMs from healthy controls and MS donors.
• Assessed the effects of LA treatment on cytokine secretion (TNF-α, IL-6, IL-1β).
• Measured phagocytosis levels and intracellular cAMP concentrations following LA exposure.

Main Results:

• LA treatment generally induced a less inflammatory phenotype in monocytes and MDMs from both healthy and MS donors.
• LA inhibited the secretion of TNF-α, IL-6, and IL-1β in monocytes, with mixed effects in MDMs.
• LA reduced phagocytosis in both cell types and increased cAMP levels in monocytes, suggesting a potential cAMP-mediated mechanism.

Conclusions:

• Lipoic acid (LA) demonstrates potential in modulating inflammatory responses relevant to multiple sclerosis (MS).
• LA may attenuate MS pathology by altering inflammatory cytokine profiles and inhibiting phagocytosis.
• The observed effects of LA, particularly the increase in cAMP, suggest a novel therapeutic pathway for MS treatment.